Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Interventions
- Registration Number
- NCT06571461
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Brief Summary
This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal adenocarcinoma after radical surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 408
- Patients able and willing to provide a written informed consent aged 18-75 years.
- Histologically confirmed resected ductal pancreatic adenocarcinoma (including adenosquamous carcinoma).
- Undergone radical resection and confirmed macroscopic complete resection (R0 and R1).
- Full recovery after surgery; able to start adjuvant treatment within 12 weeks after surgery.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- The main organs function well.
- Patients with other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, pancreatoblastoma, and solid-pseudopapillary tumor.
- Macroscopic incomplete tumor removal (R2 resection).
- Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma.
- Presence or history of metastatic or locally recurrent pancreatic adenocarcinoma.
- CA 19-9> 180 U / ml within 21 days before randomization.
- The toxicity of previous therapy has not recovered to Grade 1 or below.
- Known peripheral neuropathy (CTCAE ≥ Grade 2).
- Known deficiency of dihydropyrimidine dehydrogenase (DPD)
- Subjects with a confirmed diagnosis of Gilbert's syndrome
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NASOX:Liposomal Irinotecan; Oxaliplatin; S-1 Liposomal Irinotecan Liposomal irinotecan at a dose of 50 mg/m² is administered intravenously over 90 minutes on D1. Oxaliplatin is administered at a dose of 60 mg/m² intravenously over 2 hours on D1. S-1 at a dose of 40 to 60mg twice daily is taken orally for 7 consecutive days, followed by a 7-day break. These medications are administered once every 2 weeks for a total of 12 cycles. GX:Gemcitabine; Capecitabine Gemcitabine Gemcitabine at a dose of 1000mg/m² is administered via intravenous infusion over 30 minutes on D1, 8, and 15 of a 28-day cycle. Capecitabine at a dose of 1660mg/m² per day in two divided oral doses is taken for 21 consecutive days, followed by a 7-day rest period. These medications are administered once every 4 weeks for a total of 6 cycles. NASOX:Liposomal Irinotecan; Oxaliplatin; S-1 S-1 Liposomal irinotecan at a dose of 50 mg/m² is administered intravenously over 90 minutes on D1. Oxaliplatin is administered at a dose of 60 mg/m² intravenously over 2 hours on D1. S-1 at a dose of 40 to 60mg twice daily is taken orally for 7 consecutive days, followed by a 7-day break. These medications are administered once every 2 weeks for a total of 12 cycles. NASOX:Liposomal Irinotecan; Oxaliplatin; S-1 Oxaliplatin Liposomal irinotecan at a dose of 50 mg/m² is administered intravenously over 90 minutes on D1. Oxaliplatin is administered at a dose of 60 mg/m² intravenously over 2 hours on D1. S-1 at a dose of 40 to 60mg twice daily is taken orally for 7 consecutive days, followed by a 7-day break. These medications are administered once every 2 weeks for a total of 12 cycles. GX:Gemcitabine; Capecitabine Capecitabine Gemcitabine at a dose of 1000mg/m² is administered via intravenous infusion over 30 minutes on D1, 8, and 15 of a 28-day cycle. Capecitabine at a dose of 1660mg/m² per day in two divided oral doses is taken for 21 consecutive days, followed by a 7-day rest period. These medications are administered once every 4 weeks for a total of 6 cycles.
- Primary Outcome Measures
Name Time Method Disease-free survival (DFS) Approximately 3 years. Disease-free survival is defined as the time from the date of randomization to the date of disease recurrence or death from any cause (whichever occurs first). Disease recurrence is defined as evidence of disease recurrence demonstrated by imaging assessment with CT or MRI scan and/or pathological diagnosis indicated by biopsy.
- Secondary Outcome Measures
Name Time Method Overall survival (OS) Approximately 5 years.